Koo Foundation Sun Yat-Sen Cancer Center
About Koo Foundation Sun Yat-Sen Cancer Center
- Top Sponsors
- Top Collaborators
- Trials By Phase
- Recruitment Status
- Top Conditions
- Intervention Types
- Top Intervention Names
- Trials By Gender
Lead Sponsor
# Trials
Pfizer
9
Eli Lilly and Company
6
Boehringer Ingelheim
3
Daiichi Sankyo, Inc.
2
National Health Research Institutes, Taiwan
2
OBI Pharma, Inc
2
Odonate Therapeutics, Inc.
2
Regeneron Pharmaceuticals
2
Agenus Inc.
1
CanariaBio Inc.
1
Helsinn Healthcare SA
1
Clinical Trials at Koo Foundation Sun Yat-Sen Cancer Center
During the past decade, Koo Foundation Sun Yat-Sen Cancer Center conducted 33 clinical trials. In the 10-year time frame, 33 clinical trials started and 14 clinical trials were completed, i.e. on
average, 42.4% percent of trials that started reached the finish line to date. In the past 5 years, 9 clinical trials started and 10 clinical trials were completed. i.e. 111.1%
of trials that started reached the finish line.
Trials List
Trail ID
Brief Title
Start Date
Completion Date
Status
Enrollment
BETH Study: Treatment of HER2 Positive Breast Cancer With Chemotherapy Plus Trastuzumab vs Chemotherapy Plus Trastuzumab Plus Bevacizumab
2008-04-01
2014-07-01
Terminated
3,509
LUX-Breast 1: BIBW 2992 (Afatinib) in HER2-positive Metastatic Breast Cancer Patients After One Prior Herceptin Treatment
2010-06-22
2018-07-06
Completed
508
LUX-Breast 2; Afatinib in HER2 (Human Epidermal Growth Factor Receptor)-Treatment Failures
2011-05-24
2017-03-13
Completed
74
Quality Study of Anesthetic Technique on Breast Cancer Surgery
2012-01-01
2013-06-01
Completed
101
Trial of Active Immunotherapy With Globo H-KLH (OPT-822) in Metastatic Breast Cancer Subjects
2011-12-01
2019-08-01
Completed
349
LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy
2012-03-05
2017-12-27
Completed
795
A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study)
2013-10-14
2021-03-05
Completed
431
Clinical Trials Sponsors and Collaborators
Out of the total clinical trials conducted in "Koo Foundation Sun Yat-Sen Cancer Center" #1 sponsor was "Pfizer" with 9 trials, followed by "Eli Lilly and Company" with 6 trials
sponsored, "Boehringer Ingelheim" with 3 trials sponsored, "Daiichi Sankyo, Inc." with 2 trials sponsored and "National Health Research Institutes, Taiwan"
with 2 trials sponsored. Other sponsors include 17 different institutions and
companies that sponsored additional 24 trials in total.
In terms of collaborators to trials, out of the total clinical trials conducted in "Koo Foundation Sun Yat-Sen Cancer Center"
#1 collaborator was "Koo Foundation Sun Yat-Sen Cancer Center" with 3 trials as a collaborator, "National Taiwan University Hospital" with 3 trials as a collaborator, "AstraZeneca" with 2 trials as a collaborator, "Chang Gung Memorial Hospital" with 2 trials as a collaborator and "China Medical University Hospital" with 2 trials as a collaborator. Other collaborators include 23 different institutions and companies that were
collaborators in the rest 31 trials.
Clinical Trials Conditions at Koo Foundation Sun Yat-Sen Cancer Center
According to Clinical.Site data, the most researched conditions in "Koo Foundation Sun Yat-Sen Cancer Center" are
"Breast Neoplasms" (8 trials), "Breast Cancer" (5 trials), "Metastatic Breast Cancer" (4 trials), "Ovarian Cancer" (4 trials) and "Carcinoma, Non-Small-Cell Lung" (2 trials). Many other conditions were trialed in "Koo Foundation Sun Yat-Sen Cancer Center" in a lesser frequency.
Clinical Trials Intervention Types at Koo Foundation Sun Yat-Sen Cancer Center
Most popular intervention types in "Koo Foundation Sun Yat-Sen Cancer Center" are "Drug" (38 trials), "Biological" (5 trials), "Other" (5 trials), "Device" (2 trials) and "Genetic" (1 trials). Other intervention types were less common.
The name of intervention was led by "Abemaciclib" (5 trials), "Placebo" (5 trials), "Avelumab" (3 trials), "Capecitabine" (3 trials) and "Palbociclib" (3 trials). Other intervention names were less common.
Clinical Trials Genders at Koo Foundation Sun Yat-Sen Cancer Center
The vast majority of trials in "Koo Foundation Sun Yat-Sen Cancer Center" are
29 trials for "All" genders and 15 trials for "Female" genders.
Clinical Trials Status at Koo Foundation Sun Yat-Sen Cancer Center
Currently, there are NaN active trials in "Koo Foundation Sun Yat-Sen Cancer Center".
undefined are not yet recruiting,
9 are recruiting,
10 are Active, not recruiting,
and undefined are Enrolling by invitation.
In total, there were 11 completed trials in Koo Foundation Sun Yat-Sen Cancer Center,
1 suspended trials,
and 9 terminated clinical trials to date.
Out of the total trials that were conducted in Koo Foundation Sun Yat-Sen Cancer Center, 0 "Phase 1"
clinical trials were conducted, 8 "Phase 2" clinical
trials and 30 "Phase 3" clinical trials were conducted as
well. "Phase 4" trials included 3 trials, and there were
also 0 trials that are defined as “Not Applicable".